Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
pdmFlu vaccine · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| pdmFlu vaccine 1 | EXPERIMENTAL | - |
| pdmFlu vaccine 2 | EXPERIMENTAL | - |
| pdmFlu vaccine 3 | EXPERIMENTAL | - |
| pdmFlu vaccine 4 | EXPERIMENTAL | - |
| pdmFlu vaccine 5 | EXPERIMENTAL | - |
| pdmFlu vaccine 6 | EXPERIMENTAL | - |
| pdmFlu vaccine 7 | EXPERIMENTAL | - |
| pdmFlu vaccine 8 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Licensed influenza vaccine | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| pdmFlu vaccine | BIOLOGICAL | Intramuscular injection |
| Placebo | BIOLOGICAL | Intramuscular injection |
| Licensed influenza vaccine | BIOLOGICAL | Intramuscular injection |
Key Inclusion Criteria: \- Healthy participants who are determined by medical history, physical examination (if required), and clinical judgment of the investigator to be eligible for inclusion in the study. Key Exclusion Criteria: \- Does not meet seasonal influenza vaccine requirements per coho...
pdmFlu vaccine is an investigational modified RNA vaccine developed by Pfizer for protection against pandemic influenza, the disease referred to in French as Grippe. It is designed to prompt an immune response to influenza virus strains with pandemic potential and has been studied in healthy adult volunteers.
pdmFlu vaccine is being developed for the prevention of pandemic influenza, listed in its trial as Grippe, the French term for influenza. The Phase 1 study enrolled healthy volunteers aged 18 years and older to assess safety, tolerability, and immune response rather than to treat existing infection.
Pfizer, Inc. is developing pdmFlu vaccine. Pfizer trades on the New York Stock Exchange under the ticker PFE. The company sponsored the Phase 1 study of the modified RNA pandemic influenza vaccine, which was conducted in the United States.
pdmFlu vaccine is in Phase 1 clinical development. It is investigational and has not been approved for use. The single Phase 1 trial, NCT06179446, has been completed, and no trials of pdmFlu vaccine are currently listed as active.
pdmFlu vaccine has been studied in one clinical trial, NCT06179446, titled a study to learn how safe, tolerable, and capable of producing an immune response a modified RNA vaccine against pandemic influenza is. The Phase 1 trial was completed, enrolled 157 participants, and was randomized, double-blind, and placebo-controlled.